As the volume and complexity of biomedical data continue to grow, extracting actionable insights that directly impact patient outcomes has become a critical challenge for the life sciences sector. The integration of AI in bioinformatics is transforming how biomarkers are discovered and developed.

In this interactive webinar, the team of data scientists will be complemented by a clinician to provide perspective on how these advancements are clinically relevant and applicable with the goal of improving patient care.

This webinar will feature a real-world case study highlighting the development of Tutivia™, an innovative diagnostic tool that leverages advanced RNA signature analysis and computational biology to predict acute rejections in patients. Through this collaboration, BioLizard and Verici Diagnostics have built a robust pipeline that integrates multi-omics data and machine learning, enabling the identification of novel biomarkers, improved risk stratification, and enhanced clinical decision-making.

Of interest to researchers, clinicians, clinical trial experts, and data scientists working in precision medicine, this session will provide practical insights into management and potential of personalized diagnostics. Attendees will discover how interdisciplinary collaboration—spanning biology, bioinformatics, and AI—can unravel the complexity of large biomedical datasets, leading to earlier and more accurate risk prediction and better long-term outcomes for disease management.

In addition, Dr. Volodimir Olexiouk  introduced Bio|Verse™, BioLizard’s next-generation AI-powered platform for biomarker discovery. Bio|Verse empowers researchers to seamlessly analyze, integrate, and visualize multi-omics data, accelerating the journey from data to discovery. Don’t miss this opportunity to learn how cutting-edge bioinformatics solutions are driving innovation, reducing uncertainty, and setting new standards in organ transplant diagnostics.

KEY TAKEAWAYS:

• Discover how AI-powered bioinformatics and multi-omics integration are revolutionizing biomarker discovery.

• Learn from a real-world case study (Tutivia™) how advanced RNA signature analysis and machine learning can improve disease risk stratification and support clinical decision-making for patient care.

• See how next-generation platforms like Bio|Verse™ empower researchers to seamlessly analyze, integrate, and visualize complex biomedical data, accelerating the journey from data to actionable insights.
  
  

WHO SHOULD ATTEND:

• Translational and clinical researchers
• Clinical trial professionals
• Data scientists, computational biologists and bioinformaticians
• Pharma and biotech professionals 
• Clinicians